Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks InsideIGC Pharma, Inc. (
NYSE: IGC) a clinical-stage biotechnology company developing AI-powered Alzheimer’s disease therapies, is gaining investor attention after reporting Q1 2026 financial results and continued progress in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia.
